Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 29 min ago
Peer-reviewedCC BY-NC-ND 4.0Oncology Letters

Supplementary value of primary tumor volume for prognostic stratification in patients with T3-4 nasopharyngeal carcinoma: A retrospective cohort study

  1. 1Department of Oncology and Radiotherapy, Guilin People's Hospital, Guilin, Guangxi 541002, P.R. China

Abstract

The present retrospective study evaluated the supplementary value of gross tumor volume of the primary nasopharyngeal tumor (GTVnx) for overall survival (OS) risk stratification in patients with T3-4 nasopharyngeal carcinoma (NPC). A total of 118 patients with T3-4 NPC who received definitive intensity-modulated radiotherapy at Guilin People's Hospital (Guilin, China) between March 2020 and June 2025 were included. GTVnx was obtained from the radiotherapy planning system. A time-dependent receiver operating characteristic (ROC) curve was used to determine the exploratory cut-off for predicting 3-year OS. Survival differences were assessed using the Kaplan-Meier method and log-rank test, and Cox proportional hazards models were used to evaluate the association between GTVnx and OS. Clinical and extended models were compared using the concordance index (C-index), Akaike information criterion (AIC) and time-dependent area under the curve (AUC), and sensitivity analyses were performed to assess robustness. The median follow-up time was 34.1 months and 18 deaths occurred (15.3%). The 36-month time-dependent ROC analysis identified 78 cm3 as the exploratory cut-off for GTVnx, with an AUC of 0.709. Patients with high GTVnx had poorer OS than those with low GTVnx (log-rank P<0.001). In a multivariable Cox analysis, high GTVnx remained associated with poorer OS after adjustment for T stage and pretreatment Epstein-Barr virus DNA (EBV DNA; hazard ratio, 4.375; 95% confidence interval, 1.474–12.986; P=0.008). Adding GTVnx to the clinical model improved the C-index from 0.759 to 0.817, reduced the AIC from 135.151 to 133.085 and increased the 36-month AUC from 0.748 to 0.787. Sensitivity analyses supported the consistency of the main findings. GTVnx may provide supplementary prognostic information beyond T stage and pretreatment EBV DNA in patients with T3-4 NPC. However, the identified cut-off value and incremental prognostic value require validation in independent cohorts.

Related

  1. Weakly supervised computational pathology for prognostic stratification in locally advanced nasopharyngeal carcinoma: a multicenter external validation study
    Chao Jiang, Wenxuan Lu, Mingjun Ding +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  2. Lymph Node Regression Improves Prognostic Stratification in Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Chemoimmunotherapy: A Multicenter Retrospective Cohort Study.
    Jian Zheng, Wenbin Shen, Jianzhong Cao +13
    MedCommPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  3. Prognostic value of neutrophil-to-lymphocyte ratio in nasopharyngeal carcinoma: a systematic review and meta-analysis of 30 cohorts through June 30, 2026
    Yunliang Lu, Biaoyou Chen, Jingfeng Ye +4
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. A pretreatment TNM-metabolic vulnerability score with EBV DNA adjustment for risk stratification in non-metastatic nasopharyngeal carcinoma
    Jinghua Zhong, Chunyan Zhou, Qiang Yi +7
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyCrossref
  5. Leveraging deep learning for prognostic stratification of hepatocellular carcinoma using histopathological images
    Dengbin Wu, Jiaoyue Zhang, Mian Shi +4
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
BibTeX
@article{huang2026supplementary,
  title = {{Supplementary value of primary tumor volume for prognostic stratification in patients with T3-4 nasopharyngeal carcinoma: A retrospective cohort study}},
  author = {Hui Huang and Yusong Lu and Yingjie Ouyang and Min Pan and Xinyu Tang and Hongrui He and Tingfeng Zhang and Qi Gong and Chunqiao Chen and Qiuqiu Chen},
  journal = {Oncology Letters},
  year = {2026},
  month = oct,
  doi = {10.3892/ol.2026.15904},
  url = {https://doi.org/10.3892/ol.2026.15904},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Supplementary value of primary tumor volume for prognostic stratification in patients with T3-4 nasopharyngeal carcinoma: A retrospective cohort study
AU  - Hui Huang
AU  - Yusong Lu
AU  - Yingjie Ouyang
AU  - Min Pan
AU  - Xinyu Tang
AU  - Hongrui He
AU  - Tingfeng Zhang
AU  - Qi Gong
AU  - Chunqiao Chen
AU  - Qiuqiu Chen
PY  - 2026
DA  - 2026/10/13
JO  - Oncology Letters
DO  - 10.3892/ol.2026.15904
UR  - https://doi.org/10.3892/ol.2026.15904
AB  - The present retrospective study evaluated the supplementary value of gross tumor volume of the primary nasopharyngeal tumor (GTVnx) for overall survival (OS) risk stratification in patients with T3-4 nasopharyngeal carcinoma (NPC). A total of 118 patients with T3-4 NPC who received definitive intensity-modulated radiotherapy at Guilin People's Hospital (Guilin, China) between March 2020 and June 2025 were included. GTVnx was obtained from the radiotherapy planning system. A time-dependent receiver operating characteristic (ROC) curve was used to determine the exploratory cut-off for predicting 3-year OS. Survival differences were assessed using the Kaplan-Meier method and log-rank test, and Cox proportional hazards models were used to evaluate the association between GTVnx and OS. Clinical and extended models were compared using the concordance index (C-index), Akaike information criterion (AIC) and time-dependent area under the curve (AUC), and sensitivity analyses were performed to assess robustness. The median follow-up time was 34.1 months and 18 deaths occurred (15.3%). The 36-month time-dependent ROC analysis identified 78 cm3 as the exploratory cut-off for GTVnx, with an AUC of 0.709. Patients with high GTVnx had poorer OS than those with low GTVnx (log-rank P<0.001). In a multivariable Cox analysis, high GTVnx remained associated with poorer OS after adjustment for T stage and pretreatment Epstein-Barr virus DNA (EBV DNA; hazard ratio, 4.375; 95% confidence interval, 1.474–12.986; P=0.008). Adding GTVnx to the clinical model improved the C-index from 0.759 to 0.817, reduced the AIC from 135.151 to 133.085 and increased the 36-month AUC from 0.748 to 0.787. Sensitivity analyses supported the consistency of the main findings. GTVnx may provide supplementary prognostic information beyond T stage and pretreatment EBV DNA in patients with T3-4 NPC. However, the identified cut-off value and incremental prognostic value require validation in independent cohorts.
SN  - 1792-1074
SN  - 1792-1082
ER  -